

PATTY MURRAY, WASHINGTON, CHAIR

BERNARD SANDERS (I), VERMONT  
ROBERT P. CASEY, JR., PENNSYLVANIA  
TAMMY BALDWIN, WISCONSIN  
CHRISTOPHER S. MURPHY, CONNECTICUT  
TIM Kaine, VIRGINIA  
MARGARET WOOD HASSAN, NEW HAMPSHIRE  
TINA SMITH, MINNESOTA  
JACKY ROSEN, NEVADA  
BEN RAY LUJÁN, NEW MEXICO  
JOHN HICKENLOOPER, COLORADO

RICHARD BURR, NORTH CAROLINA  
RAND PAUL, KENTUCKY  
SUSAN M. COLLINS, MAINE  
BILL CASSIDY, LOUISIANA  
LISA MURKOWSKI, ALASKA  
MIKE BRAUN, INDIANA  
ROGER MARSHALL, KANSAS  
TIM SCOTT, SOUTH CAROLINA  
MITT ROMNEY, UTAH  
TOMMY TUBERVILLE, ALABAMA  
JERRY MORAN, KANSAS

## United States Senate

COMMITTEE ON HEALTH, EDUCATION,  
LABOR, AND PENSIONS

WASHINGTON, DC 20510-6300

EVAN T. SCHATZ, STAFF DIRECTOR  
DAVID P. CLEARY, REPUBLICAN STAFF DIRECTOR

<http://help.senate.gov>

April 5, 2022

The Honorable Rochelle Walensky, MD, MPH  
Director  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30333

Dear Director Walensky,

I write with grave concern about the decision to terminate the Title 42 order “suspending the right to introduce certain persons into the United States from countries where a quarantinable communicable disease exists”<sup>1</sup> on May 23, 2022. The Title 42 order was an important tool put into place to address concerns related to the introduction and spread of COVID-19 into the United States, including new variants. With the number of people attempting to cross the border illegally expected to increase to up to 170,000 individuals each month following the termination of this policy, I am concerned about the effect this decision will place on public health and health care systems in the United States.

I believe that I understand the Administration’s progressive politics driving the decision, but I do not believe that there is adequate science that would allow such a decision to be made.

In the announcement, CDC noted, “97.1% of the U.S. population lives in a county identified as having ‘low’ COVID-19 Community Level.”<sup>2</sup> However, as of today, CDC assesses the risk of COVID-19 transmission in Mexico to be Level 3, or high, and all other countries in Central America are at or above Level 3, except for those that CDC recommends U.S. travelers entirely avoid due to lack of information about COVID-19 transmission levels.<sup>3</sup>

CDC also cites the importance of vaccination in preventing severe disease during the Omicron surge, which CDC uses as evidence to support the decision to terminate the previous order.<sup>4</sup> However, the durability of immunity among the U.S. population over the coming months remains to be seen, as much of the population continues to be ineligible for a fourth dose. This could, in turn, lead to increases in

---

<sup>1</sup> <https://www.cdc.gov/coronavirus/2019-ncov/cdcresponse/Final-CDC-Order-Prohibiting-Introduction-of-Persons.pdf>

<sup>2</sup> <https://www.cdc.gov/media/releases/2022/s0401-title-42.html>

<sup>3</sup> <https://www.cdc.gov/coronavirus/2019-ncov/travelers/map-and-travel-notice.html>

<sup>4</sup> <https://www.cdc.gov/coronavirus/2019-ncov/cdcresponse/Final-CDC-Order-Prohibiting-Introduction-of-Persons.pdf>, p. 17.

The Honorable Rochelle Walensky, MD, MPH

April 5, 2022

Page 2

severe disease during future waves and will be exacerbated by the introduction of additional cases and likely undetected variants through illegal border crossings.

Access to treatments is similarly cited as a mitigating factor.<sup>5</sup> However, it is my understanding that the administration is unable to procure sufficient doses of these products for American citizens without additional funding from Congress.

Given these clear inconsistencies, I request a response to the following questions by COB April 7, 2022:

1. How did CDC weigh the risk of introduction of COVID-19 into the United States at the southwestern border, given CDC's COVID-19 risk level for countries within Central America?
2. How did CDC rationalize stagnating vaccination rates, the lack of availability of a fourth dose for the general public, and constraints on the procurement of additional therapeutics when making this decision?
3. What policies are being put into place to protect against COVID-19 in detention centers and other congregate settings in which individuals will be held?
4. Is HHS contributing any funds to support COVID-19 mitigation activities at the border? If yes, from what accounts, and how will these funds be used?
5. Has CDC received any estimates from the Department of Homeland Security related to the number of additional individuals that may enter the United States illegally as a result of this policy change? If yes, what were those estimates?
6. What steps is CDC taking to work with public health departments located both in border states and other states the Administration plans to send illegal immigrants to reside to prepare for potential increases in cases of COVID-19?
7. If the CDC can lift the Title 42 order, why isn't the CDC using the same understanding to lift other travel-related COVID-19 mitigation policies, such as the requirement to wear masks on planes and trains and other conveyances?

Thank you for your time and attention to this matter.

Sincerely,



Richard Burr

---

<sup>5</sup> Ibid, p. 18.